“The existing circumstance has uncovered some structural weaknesses during the EU’s medicines supply chain and also a large dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides claimed. She advised that supply chain problems be resolved in an EU pharmaceutical technique predicted to become released by the end from